Clinical Advisory Board

Suzanne F. Bradley, M.D.

Suzanne Bradley is Professor of Internal Medicine in Infectious Diseases and Geriatric Medicine at the University of Michigan in Ann Arbor, Michigan, and Staff Physician, Veterans Affairs at Ann Arbor Healthcare System, Michigan. Dr. Bradley has been involved in the development of infection control guidelines for nursing homes for the American Geriatrics Society (AGS), IDSA, and SHEA. She has served as an expert reviewer for HICPAC and is a member of the Office of the Medical Inspector Veterans Health Administration Nursing Home Infection Surveillance Taskforce. She is currently the Biosciences Section Editor for the AGS journal and has particular interest in aging and the host response to infection, antibiotic resistance in long-term care, Geriatrics, and Methicillin-resistant S. aureus (MRSA) infections. Dr. Bradley received her AB magna cum laude in Biology from Mount Holyoke College and her MD from SUNY Buffalo. She completed an Internal Medicine residency at Ohio State University Hospital and fellowships in Infectious Diseases and Geriatric Medicine at the University of Michigan. She is board-certified in Internal medicine and Infectious Diseases. Dr. Bradley is a Fellow of the Infectious Diseases Society of America (IDSA), the American College of Physicians and the Society for Healthcare Epidemiology of America.

David Chernoff, M.D.

Dr. Chernoff has extensive experience both as a practicing clinician and in biopharma management, having been Medical Director of Chiron Diagnostics from 1990-2000 and subsequently Vice President of Corporate Technology at Elan. Dr. Chernoff spent two years as an Entrepreneur-in-Residence and one year as an operating partner at the venture firm TPG. He has been the acting Chief Medical Officer of several startup biotech companies including, XDX, CardioDx, Replidyne, Tethys Biosciences, Adamas Pharmaceuticals and Crescendo Bioscience. Dr. Chernoff received a BS in Biology from Yale and an MD from New York University and completed his medical training in internal medicine, rheumatology, and infectious disease at UCSF. He has lectured broadly and published dozens of peer-reviewed articles.

Ralph Corey, M.D.

G. Ralph Corey is the Gary Hock Distinguished Professor of Global Health at Duke University, Durham, NC. He is also the Director of the Hubert/Yeargan Center for Global Health and Director of Infectious Disease Research at the Duke Clinical Research Institute. Dr Corey has extensive experience as a Principal Investigator conducting international clinical trials focused on blood stream infections, hospital acquired pneumonia, and complicated skin and soft tissue infections. During his more than 30 years of infectious disease research he has helped to create the S. aureus bacteremia group (SABG) and the International Collaboration on Endocarditis (ICE). He has also studied pericarditis and tropical diseases such as leishmania, malaria, and snake bites. Dr Corey has authored over 160 peer-reviewed publications and several book chapters. Dr. Corey earned his undergraduate degree in physics from Duke University, his medical degree from Baylor College of Medicine and completed his internship, residency, chief residency and fellowship at Duke University Medical Center. He has been honored with numerous awards including the Golden Apple Award, the Eugene A. Stead Teaching Award and the Distinguished Faculty Award.

Carol Epstein, M.D.

Dr. Epstein has been in the biopharmaceutical industry for over 25 years. She started her career in clinical development in Ayerst, then a division of American Home Products. She was Vice President and Chief Medical Officer at Immunex, where she created the company’s clinical infrastructure and led the successful development of GM-CSF, and had the same titles in ImmunoGen, a pioneer in development of antibodies linked to toxins. She is currently EVP and CMO of the consulting company, MediVector, Inc. Since Dr. Epstein’s entry in the industry her major interest has been designing and running development programs that are more effective (reaching the right decisions sooner) and efficient (creating a faster and more cost effective path to a decision ). Dr. Epstein has provided consulting services to big and small pharmas since the mid 1990s, and contributes to both the technical and team aspects of drug development. As part of ensuring that these twin goals can be consistently attained, MediVector has designed a pioneering web-based clinical trial/program information technology based management system. The system’s hallmark is its decision support tools that it makes risk management much more transparent to all stakeholders in the developmental process, a new paradigm that has been used to grow a drug candidates into a blockbusters. Dr. Epstein, a board certified rheumatologist, received her B.S. from MIT and M.D. degree from Yale, and did her internal medicine and fellowship training at NYU-Bellevue.

Charles Fisher, M.D.

Dr. Fisher has over 20 years of experience in clinical research trials and Phase I to IV drug development. He currently serves as Chief Medical Officer, Executive Vice President Clinical & Regulatory Affairs at Cardiome. He was most recently divisional Vice President of Global Pharmaceutical Development at Abbott Laboratories, responsible for the global development of pharmaceuticals, biologics and drug coated medical devices. Dr. Fisher was previously an Executive Director and Clinical Research Fellow at Eli Lilly & Co. During his time with Eli Lilly & Co., he was involved in Xigris development and responsible for developing business strategy for critical care, cardiovascular, inflammation and bio-products, therapeutics areas, identification of disease state targets, and business development. Prior to joining industry, Dr. Fisher was Professor and Head of Critical Care Medicine at the Cleveland Clinic Foundation, where he designed, conducted and executed over 20 clinical trials in sepsis as global Principal Investigator. From 1977-1997, Dr. Fisher held various professor and director positions at the University of Manitoba, the University of California at Davis Medical Center, Case Western Reserve University and the Cleveland Clinic Foundation

Kenneth Foon, M.D.

Dr. Foon is Head of Leukemia at the Nevada Cancer Institute. He previously served as deputy director for Clinical Investigations at the University of Pittsburgh Cancer Institute, where he co-directed the Biological Therapeutics and Hematological Malignancy Programs. He was also professor of Internal Medicine, Division of Hematology and Oncology at the University of Pittsburgh Medical School. Earlier in his distinguished career, Dr. Foon was Director of Clinical Development for Oncology at Abgenix, Inc. and clinical professor of Medicine, Division of Oncology at Stanford University Medical School. He has focused his work on immunologic/biologic approaches to cancer therapy, predominantly leukemia and lymphoma, and is the author and co-author of more than 325 peer-reviewed scientific publications, book chapters and invited scientific publications. Dr. Foon received his B.S. and M.D. degrees from Wayne State University. He was an intern in Internal Medicine at the University of California, San Diego and spent three years at the National Institutes of Heath. He completed his residency in internal medicine at Georgetown University/Washington, VA, and trained in hematology and oncology at the University of California, Los Angeles.

Robert H. Rubin, M.D., F.A.C.P., F.C.C.P.

Dr. Rubin is the Gordon and Marjorie Osborne Chair of Health Sciences and Technology (HST), the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology; Director of the HST Center for Experimental Pharmacology and Therapeutics; Co-Director of the Clinical Investigator Training Program at Harvard and MIT and Professor of Medicine at Harvard Medical School. As clinician, he is Chief of Surgical and Transplant in Infectious Disease at the Massachusetts General Hospital and has been recently named the Co-Director of the Division of Infectious at the Brigham and Women’s Hospital. Dr. Rubin received his B.A. Williams College (magna cum laude; Phi Beta Kappa) General Motors National Scholar and M.D. from Harvard Medical School (cum laude) and has spent much of his clinical career studying and caring for transplant patients with infectious disease. He has developed new strategies for preventing the most important infections and novel antimicrobial approaches that are effective not only in transplant patients, but also in such other immunocomprimized patient populations such as those with AIDS and cancer. He is the author of more than 350 publications, including 5 books, in the field of infectious disease. He is the chairman of the Infectious Disease Section of Transplantation Society, a member of nine editorial boards, and Editor-in-Chief of Transplant Infectious Disease. Additionally, Dr. Rubin is also a guest faculty at the Groningen, Netherlands.

H. Grant Stiver, M.D.

Dr. Stiver has been a pioneer of innovative management of infectious disease, including the practice of home self-administration of intravenous antibiotics. He has participated in numerous clinical trials evaluating the efficacy of antibacterial drugs and has an active clinical practice. Dr. Stiver is currently the Assistant Head of the Division of Infectious Disease at the University of British Columbia where he is also a Professor. Prior to his time at UBC, Dr. Stiver was Acting Head of the Section of Infectious Diseases and a Professor of Medicine and Medical Microbiology at the University of Manitoba where he earned his M.D.